Bauer Eugene reported grant involving 100,000 derivative units of Evommune, Inc. on Nov 13, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Medical Officer
Chief Medical Officer
Filed Nov 17, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
—Shares × reported price
Shares traded
100,000Stock Option (Right to buy)
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
100,000Direct
Trade date
Nov 13, 2026Grant
Filed
Nov 17, 2026, 4:37 PM ET4-day reporting delay
Accession
0001678620-26-000005Code A · Transaction 403735
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 13, 2026Disposition to issuer100,000——Trade 403734
Nov 13, 2026Disposition to issuer51,117——Trade 403736
Nov 13, 2026Grant51,117——Trade 403737
4 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

EVMN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
EVMN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −24%1w ago −13%1d ago +5.1%
Returns since7d30d90d180d1y

Footnotes in full

F1: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 8, 2025. F2: The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; (ii) a Change in Control, as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"); and (iii) the Reporting Person's death or Disability or termination of employment by the Issuer without Cause (each as defined in the 2025 Plan) or resignation following a Change in Control for Good Reason (as defined in the Reporting Person's employment agreement, if applicable), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option. F3: One fourth (1/4) of the shares subject to the option award shall vest on December 8, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. F4: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 16, 2026. F5: One fourth (1/4) of the shares subject to the option award shall vest on April 16, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.